23 August 2024
MYCELX Technologies Corporation
("MYCELX" or the "Company") (AIM:MYX)
Director Dealings & Total Voting Rights
MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company established to transform the environmental impact of industry, announces, further to the Placing and Subscription this morning, the following participation by Directors of the Company.
|
Director |
Shares held prior to Admission |
New Shares Purchased |
Shares held post Admission |
Percentage of Enlarged Issued Share Capital |
|
Thomas Lamb |
325,175 |
48,836 |
374,011 |
1.54% |
|
Connie Mixon1 |
2,803,944 |
100,632 |
2,931,576 |
12.06% |
|
Andre Schnabl |
118,011 |
48,836 |
166,847 |
0.69% |
1 Mrs. Mixon's shareholding includes 229,008 shares in the Company held by her spouse.
Total Voting Rights
In conformity with the FCA's Disclosure Guidance and Transparency Rules (the "Rules") provision 5.6.1, the Company would like to notify the market that following Admission on 4 September 2024 its issued share capital will consist of 24,315,271 Common Shares of US$0.025 each.
Shareholders should use 24,315,271 as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Rules.
Terms and definitions used in this announcement shall have the same meaning as ascribed to them in the Proposed Placing and Subscription Announcement released at 7:00 a.m. on 23 August 2024, unless the context requires otherwise.
For further information please contact:
|
MYCELX Technologies Corporation Connie Mixon, CEO Kim Slayton, CFO
|
Tel: +1 888 306 6843 |
|
Canaccord Genuity Limited (Nominated Adviser and Sole Broker) Henry Fitzgerald-O'Connor Charlie Hammond
|
Tel: +44 20 7523 8000 |
|
Celicourt Communications (Financial PR) Mark Antelme Jimmy Lea Charlie Denley-Myerson
|
Tel: +44 20 7770 6424 |
Notifications of transactions of persons discharging managerial responsibility or connected persons
|
1
|
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a)
|
Name |
1. Thomas Lamb 2. Connie Mixon 3. Andre Schnabl |
||||
|
2
|
Reason for the notification |
|||||
|
a)
|
Position/status
|
1. Non-Executive Chairman 2. Chief Executive Officer 3. Non-Executive Director |
||||
|
b)
|
Initial notification /Amendment |
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a)
|
Name
|
Mycelx Technologies Corporation |
||||
|
b)
|
LEI
|
213800UJZINIK2VD1G48
|
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument Identification code |
Common shares of US$0.025 US62847T2024 |
||||
|
b)
|
Nature of the transaction |
Purchase of Common Shares |
||||
|
c)
|
Price(s) and volume(s) |
|
||||
|
d)
|
Aggregated information - Aggregated volume - Price |
N/A N/A
|
||||
|
e)
|
Date of the transaction
|
23 August 2024 |
||||
|
f)
|
Place of the transaction |
London Stock Exchange |
||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
